CAPR FDA extends deramiocel BLA review target to November 22, 2026
Capricor Therapeutics says the FDA has extended the PDUFA target action date for deramiocel BLA review to November 22, 2026.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.